EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Complement system activation: bridging physiology, pathophysiology, and therapy

Elie Azoulay iD, Julien Zuber, Ahmed Aziz Bousfiha, Yun Long, Ying Tan, Sushan Luo, Meriem Essafti, Djillali Annane

Intensive Care Medicine · 2024-11 · 50 (11) · 1791-1803

DOI: 10.1007/s00134-024-07611-4 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Intensive Care Medicine, online erschienen am 10.09.2024. Verfasst von Elie Azoulay und 7 weiteren Autor:innen. Beteiligte Einrichtung: Intensive Care Unit, Saint-Louis University Hospital, AP-HP, Paris Cité University, Paris, France. elie.azoulay@aphp.fr. Hauptthemen laut MEDLINE: Complement Activation, COVID-19, Atypical Hemolytic Uremic Syndrome, Complement Inactivating Agents. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 94 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The complement system is a set of over 50 proteins that constitutes an essential part of the innate immune system. Complement system activation involves an organized proteolytic cascade. Overactivation of complement system activation is the main pathogenic mechanism of several diseases and contributes to the manifestations of many other conditions. This review describes the normal complement system and the role for complement dysregulation in critical illnesses, notably sepsis and acute respiratory distress syndrome. Complement activation is involved in the immune system response to pathogens but, when excessive, can contribute to tissue damage, runaway inflammation, and capillary leakage syndrome. Complement overactivation may play a key role in severe forms of coronavirus disease 2019 (COVID-19). Two diseases whose manifestations are mainly caused by complement overactivation, namely, atypical hemolytic and uremic syndrome (aHUS) and myasthenia gravis, are discussed. A diagnostic algorithm for aHUS is provided. Early complement-inhibiting therapy has been proven effective. When renal transplantation is required, complement-inhibiting drugs can be used prophylactically to prevent aHUS recurrence. Similarly, acetylcholine-receptor autoantibody-positive generalized myasthenia gravis involves complement system overactivation and responds to complement inhibition. The two main complement inhibitors used in to date routine are eculizumab and ravulizumab. The main adverse event is Neisseria infection, which is rare and preventable, but can be fatal. The complement system is crucial to health but, when overactivated, can cause or contribute to disease. Effective complement inhibitors are now available, although additional data are required to determine optimal regimens. Further research is also needed to better understand the complement system, develop advanced diagnostic tools, and identify markers that allow the personalization of treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Complement ActivationCOVID-19Atypical Hemolytic Uremic SyndromeComplement Inactivating AgentsHumansMyasthenia GravisSARS-CoV-2Complement System ProteinsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Acute respiratory distress syndromeAtypical hemolytic–uremic syndromeComplement activationComplement system proteinsCritical illnessMyasthenia gravisSepsisSevere COVID-19

Substanzen

Complement Inactivating AgentseculizumabComplement System ProteinsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Intensive Care Unit, Saint-Louis University Hospital, AP-HP, Paris Cité University, Paris, France. elie.azoulay@aphp.fr.
  • Department of Kidney and Metabolic Diseases, Transplantation and Clinical Immunology, Necker University Hospital, AP-HP, Paris, France.
  • Department of Pediatric Infectious and Immunological Diseases, IbnRochd University Hospital, Casablanca, Morocco.
  • Laboratory of Clinical Immunology, Inflammation and Allergy (LICIA), Casablanca, Morocco.
  • School of Medicine and Pharmacy, Hassan II University, Casablanca, Morocco.
  • Department of Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China.

ORCID-Profile: Elie Azoulay

Zitieren

APA

Azoulay, E., Zuber, J., Bousfiha, A. A., Long, Y., Tan, Y., Luo, S., Essafti, M., & Annane, D. (2024). Complement system activation: bridging physiology, pathophysiology, and therapy. Intensive Care Medicine, 50(11), 1791-1803. https://doi.org/10.1007/s00134-024-07611-4

Vancouver

Azoulay E, Zuber J, Bousfiha AA, Long Y, Tan Y, Luo S, et al. Complement system activation: bridging physiology, pathophysiology, and therapy. Intensive Care Medicine. 2024;50(11):1791-1803. doi:10.1007/s00134-024-07611-4

BibTeX
@article{Azoulay2024,
  author = {Azoulay, Elie and Zuber, Julien and Bousfiha, Ahmed Aziz and Long, Yun and Tan, Ying and Luo, Sushan and Essafti, Meriem and Annane, Djillali},
  title = {Complement system activation: bridging physiology, pathophysiology, and therapy},
  journal = {Intensive Care Medicine},
  year = {2024},
  volume = {50},
  number = {11},
  pages = {1791--1803},
  doi = {10.1007/s00134-024-07611-4}
}
Kostenlos starten →